Center for Genetics and Molecular Medicine, Department of Biochemistry and Molecular Biology, and James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky 40292, USA.
Cancer Res. 2012 Nov 15;72(22):6002-12. doi: 10.1158/0008-5472.CAN-12-0748. Epub 2012 Sep 19.
Low-penetrance alleles associated with breast cancer risk have been identified in population-based studies. Most risk loci contain either no or multiple potential candidate genes. Rat mammary carcinoma susceptibility 1b (Mcs1b) is a quantitative trait locus on RN02 that confers decreased susceptibility when Copenhagen (COP)-resistant alleles are introgressed into a Wistar Furth (WF)-susceptible genome. Five WF.COP congenic lines containing COP RN02 segments were compared. One line developed an average of 3.4 ± 2.0 and 5.5 ± 3.6 mammary carcinomas per rat ± SD when females were Mcs1b-resistant homozygous and Mcs1b heterozygous, respectively. These phenotypes were significantly different from susceptible genotype littermates (7.8 ± 3.1 mean mammary carcinomas per rat ± SD, P = 0.0001 and P = 0.0413, respectively). All other congenic lines tested were susceptible. Thus, Mcs1b was narrowed to 1.8 Mb of RN02 between genetic markers ENSRNOSNP2740854 and g2UL2-27. Mammary gland-graft carcinoma susceptibility assays were used to determine that donor (P = 0.0019), but not recipient Mcs1b genotype (P = 0.9381), was associated with ectopic mammary carcinoma outcome. Rat Mcs1b contains sequence orthologous to human 5q11.2, a breast cancer susceptibility locus identified in multiple genome-wide association studies. Human/rat MAP3K1/Map3k1 and mesoderm induction early response (MIER; MIER3)/MIER3 are within these orthologous segments. We identified MIER3 as a candidate Mcs1b gene based on 4.5-fold higher mammary gland levels of MIER3 transcripts in susceptible compared with Mcs1b-resistant females. These data suggest that the human 5q11.2 breast cancer risk allele marked by rs889312 is mammary gland autonomous, and MIER3 is a candidate breast cancer susceptibility gene.
在基于人群的研究中已经鉴定出与乳腺癌风险相关的低外显率等位基因。大多数风险位点要么不含潜在的候选基因,要么含有多个候选基因。大鼠乳腺肿瘤易感性 1b(Mcs1b)是 RN02 上的一个数量性状位点,当哥本哈根(COP)抗性等位基因被引入到 Wistar Furth(WF)易感基因组中时,它会降低易感性。比较了含有 COP RN02 片段的 5 个 WF.COP 近交系。一条线在雌性 Mcs1b 抗性纯合和 Mcs1b 杂合时,分别平均每只大鼠发展出 3.4 ± 2.0 和 5.5 ± 3.6 个乳腺肿瘤。这些表型与易感基因型同窝仔鼠显著不同(每只大鼠平均乳腺肿瘤 7.8 ± 3.1,P = 0.0001 和 P = 0.0413)。所有其他测试的近交系均易感。因此,Mcs1b 被缩小到 RN02 上的 1.8 Mb 之间的遗传标记 ENSRNOSNP2740854 和 g2UL2-27。乳腺移植癌易感性测定用于确定供体(P = 0.0019),而不是受体 Mcs1b 基因型(P = 0.9381)与异位乳腺肿瘤结局有关。大鼠 Mcs1b 含有与人类 5q11.2 同源的序列,5q11.2 是多个全基因组关联研究中确定的乳腺癌易感性位点。人类/大鼠 MAP3K1/Map3k1 和中胚层诱导早期反应(MIER;MIER3)/MIER3 位于这些同源片段内。我们基于易感雌性乳腺组织中 MIER3 转录物的 4.5 倍高表达,将 MIER3 鉴定为候选 Mcs1b 基因。这些数据表明,由 rs889312 标记的人类 5q11.2 乳腺癌风险等位基因是乳腺自主性的,而 MIER3 是候选乳腺癌易感基因。